DOW JONES27,960.80-1031.61 -3.56%
S&P 5003,225.89-111.86 -3.35%
NASDAQ9,221.28-355.31 -3.71%

Ladenburg Thalman Maintains Buy, $27 Target On Novavax Notes Co's 'insect-based vaccine platform is ideally suited to address pandemic flu outbreaks'

'Per our conversations with management, it’s possible for the company to develop a 2019-nCov vaccine that is ready for manufacturing scale-up in 90 days, but it’s still likely that any regulatory

Benzinga · 01/27/2020 15:08

'Per our conversations with management, it’s possible for the company to develop a 2019-nCov vaccine that is ready for manufacturing scale-up in 90 days, but it’s still likely that any regulatory clearance would require toxicity and stability studies, plus animal studies, before any human testing could begin.'